Jul 10, 2026 08:02AM
Jul 10, 2026 08:00AM
Jul 6, 2026 09:00AM
Jun 17, 2026 08:00AM
Jun 17, 2026 08:00AM
Jun 4, 2026 08:02AM
Jun 4, 2026 08:00AM MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
May 27, 2026 08:00AM
May 27, 2026 08:00AM
May 14, 2026 08:01AM
May 14, 2026 08:00AM
May 13, 2026 08:04AM
May 13, 2026 08:00AM
Mar 4, 2026 08:00AM MIRA Pharmaceuticals completes phase 1 trial for oral pain drug
Mar 4, 2026 08:00AM
Feb 3, 2026 07:31AM
Feb 3, 2026 07:30AM
Oct 24, 2025 07:30AM
Oct 24, 2025 07:30AM
Sep 16, 2025 07:30AM
Sep 16, 2025 07:30AM MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
Aug 19, 2025 08:30AM
Aug 19, 2025 08:30AM
Aug 12, 2025 08:32AM
Aug 12, 2025 08:30AM
Jul 30, 2025 07:30AM
Jul 30, 2025 07:30AM
Jul 29, 2025 07:31AM MIRA Pharmaceuticals receives FDA clearance for Ketamir-2 neuropathic pain trial
Jul 29, 2025 07:30AM
May 6, 2025 08:02AM
May 6, 2025 08:00AM
Apr 23, 2025 08:04AM
Apr 23, 2025 08:00AM
Apr 16, 2025 08:03AM
Apr 16, 2025 08:00AM MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
Apr 1, 2025 08:00AM
Mar 24, 2025 07:33AM
Mar 24, 2025 07:30AM
Mar 13, 2025 08:00AM
Mar 4, 2025 08:02AM
Mar 4, 2025 08:00AM
Dec 19, 2024 09:02AM Mira Pharma (MIRA) Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
Dec 19, 2024 09:00AM
Dec 10, 2024 08:34AM
Dec 10, 2024 08:30AM
Oct 28, 2024 07:41AM
Oct 28, 2024 07:30AM
Oct 21, 2024 07:47AM
Oct 21, 2024 07:30AM MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Sep 27, 2024 07:32AM

325,893 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All